ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Toremifene citrate improves HDL in men on testosterone therapy
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 104322" data-attributes="member: 3"><p>The Journal of Urology</p><p>Volume 199, Issue 4, Supplement, April 2018, Page e1171</p><p></p><p>Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II</p><p></p><p>MP85-06 TOREMIFENE CITRATE IMPROVES HIGH-DENSITY LIPOPROTEIN LEVELS IN MEN ON TESTOSTERONE REPLACEMENT THERAPY</p><p></p><p></p><p>INTRODUCTION AND OBJECTIVES</p><p>Decreases in high-density lipoprotein (HDL) levels have been observed in men on testosterone therapy (TTh). Niacin is commonly used as a therapy for low HDL, although its side effect (SE) profile often leads to frequent discontinuation. Toremifine citrate is an oral selective estrogen modulator (SERM) that is well tolerated and can improve lipid profiles by raising HDL levels in both breast and prostate cancer patients. Here we assess the role of toremifene in the management of HDL abnormalities in men on TTh.</p><p></p><p>METHODS</p><p>Men on TTh with low HDL levels (<39 mg/dL) at a single andrology clinic treated between October 2015 and August 2017 with either toremifine (60 mg daily), niacin (titrated to 1,000 mg daily over 2 months) plus krill oil (1,000 mg daily) (NKO), or no treatment (patient refusal) were reviewed in a retrospective intent-to-treat analysis. Patient age, type of TTh, length of follow-up, and baseline and subsequent non-fasting lipid panels, total testosterone (TT) levels, and estrogen (E) levels were determined. Analysis of variance (ANOVA) was used to determine differences between groups.</p><p></p><p>RESULTS</p><p>A total of 75 men with low HDL levels on injectable TTh were included (34 treated with toremifine, 17 treated with NKO, and 24 untreated). No differences in the mean (SD) age between the cohorts (39.2 (10.2) years for whole cohort), baseline laboratory values, or the mean duration of follow-up (6.4 (4.1) months, for whole cohort). Changes in laboratory values are listed in Table 1. Only the change in HDL was significant between the groups during follow-up, with both toremifine and NKO resulting in significant improvements in HDL when compared with untreated men (p = 0.02 and 0.01, respectively). No significant difference in the change in HDL between toremifine vs NKO was observed. 3 men (17.6%) stopped niacin prior to follow up secondary to intolerable SEs (flushing), whereas no men stopped toremifine due to SEs.</p><p></p><p>CONCLUSIONS</p><p>Toremifine results in improvement in HDL in men with low HDL on TTh similar to that observed with niacin + krill oil. However, toremifine is better tolerated than niacin and could serve as an reasonable alternative treatment for low HDL in men on TTh. Prospective studies are needed to validate these results.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 104322, member: 3"] The Journal of Urology Volume 199, Issue 4, Supplement, April 2018, Page e1171 Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II MP85-06 TOREMIFENE CITRATE IMPROVES HIGH-DENSITY LIPOPROTEIN LEVELS IN MEN ON TESTOSTERONE REPLACEMENT THERAPY INTRODUCTION AND OBJECTIVES Decreases in high-density lipoprotein (HDL) levels have been observed in men on testosterone therapy (TTh). Niacin is commonly used as a therapy for low HDL, although its side effect (SE) profile often leads to frequent discontinuation. Toremifine citrate is an oral selective estrogen modulator (SERM) that is well tolerated and can improve lipid profiles by raising HDL levels in both breast and prostate cancer patients. Here we assess the role of toremifene in the management of HDL abnormalities in men on TTh. METHODS Men on TTh with low HDL levels (<39 mg/dL) at a single andrology clinic treated between October 2015 and August 2017 with either toremifine (60 mg daily), niacin (titrated to 1,000 mg daily over 2 months) plus krill oil (1,000 mg daily) (NKO), or no treatment (patient refusal) were reviewed in a retrospective intent-to-treat analysis. Patient age, type of TTh, length of follow-up, and baseline and subsequent non-fasting lipid panels, total testosterone (TT) levels, and estrogen (E) levels were determined. Analysis of variance (ANOVA) was used to determine differences between groups. RESULTS A total of 75 men with low HDL levels on injectable TTh were included (34 treated with toremifine, 17 treated with NKO, and 24 untreated). No differences in the mean (SD) age between the cohorts (39.2 (10.2) years for whole cohort), baseline laboratory values, or the mean duration of follow-up (6.4 (4.1) months, for whole cohort). Changes in laboratory values are listed in Table 1. Only the change in HDL was significant between the groups during follow-up, with both toremifine and NKO resulting in significant improvements in HDL when compared with untreated men (p = 0.02 and 0.01, respectively). No significant difference in the change in HDL between toremifine vs NKO was observed. 3 men (17.6%) stopped niacin prior to follow up secondary to intolerable SEs (flushing), whereas no men stopped toremifine due to SEs. CONCLUSIONS Toremifine results in improvement in HDL in men with low HDL on TTh similar to that observed with niacin + krill oil. However, toremifine is better tolerated than niacin and could serve as an reasonable alternative treatment for low HDL in men on TTh. Prospective studies are needed to validate these results. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Toremifene citrate improves HDL in men on testosterone therapy
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top